Form 8-K - Current report:
SEC Accession No. 0001213900-21-046872
Filing Date
2021-09-07
Accepted
2021-09-07 16:05:35
Documents
15
Period of Report
2021-09-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea146729-8k_citiuspharrm.htm   iXBRL 8-K 39925
2 PRESS RELEASE ea146729ex99-1_citiuspharrm.htm EX-99.1 19627
3 GRAPHIC image_001.jpg GRAPHIC 4477
  Complete submission text file 0001213900-21-046872.txt   298077

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ctxr-20210901.xsd EX-101.SCH 3706
5 XBRL DEFINITION FILE ctxr-20210901_def.xml EX-101.DEF 27646
6 XBRL LABEL FILE ctxr-20210901_lab.xml EX-101.LAB 36630
7 XBRL PRESENTATION FILE ctxr-20210901_pre.xml EX-101.PRE 26264
8 EXTRACTED XBRL INSTANCE DOCUMENT ea146729-8k_citiuspharrm_htm.xml XML 5278
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 211239350
SIC: 2834 Pharmaceutical Preparations